Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Trading Ideas

Aptinyx’s Chronic Pain Candidate Fails To Top Placebo In Mid-Stage Study

By Vandana Singh
August 12, 9:32 AM
Aptinyx Inc (NASDAQ: APTX) has announced results from a Phase 2b study evaluating the effects of NYX-2925 in patients with fibromyalgia, characterized by muscular or musculoskeletal pain with stiffness and localized tenderness at specific points.

APTX

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Trading Ideas

UNITY Biotech Shares More Than Double On Positive Drug Data For Diabetes Associated Vision Loss

By Vandana Singh
August 12, 9:18 AM
UNITY Biotechnology Inc (NASDAQ:UBX) shares are skyrocketing after 12- and 18-week data from its Phase 2 BEHOLD study of UBX1325 for…

UBX

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Johnson & Johnson To Stop Selling Talc-Based Powder

By Vandana Singh
August 12, 7:48 AM
Johnson & Johnson (NYSE:JNJ) said it plans to stop selling its legacy talc-based baby-powder products globally in 2023, a move amid…

JNJ

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News
  • Penny Stocks

Homology Medicines Announces Preclinical Gene Therapy Candidate For Genetic Storage Disorder

By Vandana Singh
August 12, 7:46 AM
Homology Medicines Inc (NASDAQ: FIXX) announced the details of HMI-204, its optimized, in vivo, one-time gene therapy candidate for metachromatic leukodystrophy (MLD). 

FIXX

Read More
3 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News
  • Penny Stocks
  • Small Cap

Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan
August 11, 6:07 PM
The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug…

ALXO

Read More
1 minute read
  • Biotech
  • General
  • Health Care

AVITA Medical Shares Climb On Topline Results From Soft Tissue Reconstruction Study, Sees PMA Submission By Year-end

By Ragothaman Srinivasan
August 11, 5:29 PM
AVITA Medical (NASDAQ: RCEL) announced topline results from its pivotal trial evaluating the safety and effectiveness of the RECELL System combined with meshed autograft for reduction of donor skin harvesting in soft tissue reconstruction.

RCEL

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • General
  • Health Care
  • Initiation
  • Movers
  • News
  • Trading Ideas

This Nasal Spray For Eye Disease Stock Is ‘Attractive’, Has Potential 160% Upside

By Vandana Singh
August 11, 3:11 PM
Chardan initiated coverage on Oyster Point Pharma Inc (NASDAQ:OYST) with a Buy rating and a price target of $22. The lead product,…

ABBV

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Earnings
  • General
  • Health Care
  • News
  • Penny Stocks
  • Price Target

Despite Competition This Analyst Finds BrainsWay Attractive

By Vandana Singh
August 11, 2:50 PM
Yesterday BrainsWay Ltd (NASDAQ:BWAY) reported Q2 sales of $8.0 million, up 14% Y/Y, missing the consensus of $8.47 million, amid a…

BWAY

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News
  • Penny Stocks

This Penny Stock Biotech Offloads Eye Portfolio To Focus On RNA-Editing

By Vandana Singh
August 11, 2:48 PM
ProQR Therapeutics N.V. (NASDAQ:PRQR) said it would look for a partner to take the company’s ophthalmology portfolio further into clinical trials. …

LLY

Read More
1 minute read
  • Biotech
  • Financing
  • General
  • Health Care
  • News
  • Penny Stocks

Allena Pharma Needs To Raise Capital To Continue As A Going Concern

By Vandana Singh
August 11, 2:47 PM
Allena Pharmaceuticals Inc (NASDAQ:ALNA) says it lacks the financial resources to conduct studies for ALLN-346 for hyperuricemia and gout in the…

ALNA

Posts pagination

Previous 1 … 445 446 447 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service